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Abstract 
Background: Tuberculous meningitis (TBM) caused by Mycobacterium tuberculosis resistant to antituberculosis drugs 
is an increasingly common clinical problem. This study aimed to evaluate drug resistance profiles of TBM isolates in 
adult patients in nine European countries involving 32 centers to provide insight into the empiric treatment of TBM.
Methods: Mycobacterium tuberculosis was cultured from the cerebrospinal fluid (CSF) of 142 patients and was tested 
for susceptibility to first‑line antituberculosis drugs, streptomycin (SM), isoniazid (INH), rifampicin (RIF) and ethambutol 
(EMB).
Results: Twenty of 142 isolates (14.1 %) were resistant to at least one antituberculosis drug, and five (3.5 %) were 
resistant to at least INH and RIF, [multidrug resistant (MDR)]. The resistance rate was 12, 4.9, 4.2 and 3.5 % for INH, SM, 
EMB and RIF, respectively. The monoresistance rate was 6.3, 1.4 and 0.7 % for INH, SM and EMB respectively. There was 
no monoresistance to RIF. The mortality rate was 23.8 % in fully susceptible cases while it was 33.3 % for those exhibit‑
ing monoresistance to INH, and 40 % in cases with MDR‑TBM. In compared to patients without resistance to any first‑
line drug, the relative risk of death for INH‑monoresistance and MDR‑TBM was 1.60 (95 % CI, 0.38–6.82) and 2.14 (95 % 
CI, 0:34–13:42), respectively.
Conclusion: INH‑resistance and MDR rates seemed not to be worrisome in our study. However, considering their 
adverse effects on treatment, rapid detection of resistance to at least INH and RIF would be most beneficial for design‑
ing anti‑TB therapy. Still, empiric TBM treatment should be started immediately without waiting the drug susceptibil‑
ity testing.
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Background
Tuberculosis (TB) continues to be a serious and challeng-
ing global health problem. World health organization 
(WHO) estimated that 9 million people developed TB 
and 1.5 million people died of this disease in 2013. The 
same report emphasized the development of multidrug 
resistant tuberculosis [MDR-TB, defined as resistance to 
at least isoniazid (INH) and rifampicin (RIF)] in an esti-
mated 480,000 people in 2013, of which only half of them 
could be diagnosed [1]. Extrapulmonary tuberculosis 
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accounts for more than 15 % of all tuberculosis cases [1]. 
Tuberculous meningitis (TBM) is a very serious form of 
extrapulmonary TB, accounting for 5–10 % and requiring 
prompt treatment [2]. The mortality rate for TBM ranges 
between 20 and 69 % worldwide with up to half of survi-
vors experiencing irreversible sequelae. One of the most 
important factors affecting the prognosis is early diagno-
sis and proper treatment [3].
The sensitivities of cerebrospinal fluid (CSF) micro-
scopic examination and culture are low because of 
insufficient numbers of bacilli in the CSF. Moreover, 
prolonged periods of time for recovery lead to signifi-
cant delays in obtaining the results of drug susceptibility 
tests (DSTs). However, initiation of effective anti-tuber-
culous treatment in the early stages of TBM is signifi-
cantly associated with reduced rates of mortality and 
sequelae [4]. Thus, the diagnosis of TBM is often based 
on epidemiological, clinical and radiological findings, fol-
lowed by standard empirical treatment without awaiting 
culture results [2, 4]. However, the effectiveness of the 
standard treatment is low in patients with TBM caused 
by drug-resistant strains. INH has the highest CSF pen-
etration among first-line antituberculosis agents and 
even monoresistance to INH may adversely affect the 
treatment outcomes. Multidrug Resistant Tuberculous 
Meningitis (MDR-TBM) increases worldwide and the 
prognosis is even worse in patients with MDR-TBM [5, 
6].
Reports on drug resistance rates in TBM are limited 
and often anecdotal due to difficulties in obtaining the 
results of DST [7, 8]. In this study, we evaluated drug 
resistance profiles of TBM in adult patients in nine Euro-
pean countries involving 32 centers in an attempt to pro-
vide more insight into the empiric treatment of TBM.
Methods
Haydarpasa-IV is a retrospective, multinational, and 
multicenter study. The initial two analyses from the Hay-
darpasa database, the first recommending a diagnostic 
algorithm and the second one providing a new severity 
index, were published previously [3, 9]. A Microsoft Win-
dows-based computer database was designed and data 
were collected from 32 centers in nine countries (Turkey, 
Slovenia, Serbia, Romania, Hungary, France, Denmark, 
Croatia and Albania). The study protocol was approved 
by the Institutional Review Board of Istanbul Fatih Sultan 
Mehmet Training and Research Hospital.
DST results of M. tuberculosis strains isolated from 
CSF samples of 142 adult patients [76 females (53.5  %); 
mean age 44.9  ±  19.8  years] with TBM between 2000 
thorough 2012 were evaluated. The study group com-
prised of 124 new TBM cases (87.3 %) and 15 previously 
treated cases (10.6 %). In three patients, previous history 
was missing in the hospital records (2.1 %). The inclusion 
criteria were age older than 14 years, presence of at least 
one positive CSF culture result and culture-based DST 
results for the first-line drugs.
A total of 142 M. tuberculosis isolates recovered from 
CSF samples were tested by culture-based DSTs for sus-
ceptibility to four first-line drugs, streptomycin (SM), 
INH, RIF and ethambutol (EMB). Culture-based DSTs 
were performed using different methods in individual 
centers. Of 142 isolates, 116 (81.7  %) were tested using 
automated culture systems including BACTEC MGIT 
960 (n = 94), BACTEC 460 (n = 9), BACTEC 9000 MB 
(n =  7) (Becton–Dickinson Diagnostic Systems, Sparks, 
MD, USA) and BacT/Alert MB (n  =  6) (bioMérieux 
Diagnostics, Durham, NC, USA) in full compliance with 
the manufacturers’ recommendations. The remaining 
26 isolates were tested by the solid culture proportion 
method on Lowenstein–Jensen medium (n  =  22) and 
on Middlebrook 7H10 agar (n  =  4) using the standard 
protocol.
Data were analyzed using the SPSS software package, 
version 16.0 (SPSS Inc, Chicago, IL, USA). We deter-
mined the unadjusted association between resistance 
(INH-monoresitance and MDR) and subsequent death 
by using the χ2 test and Fischer’s exact test, and P < 0.05 
was accepted as significant. We calculated an odds ratio 
and a 95 % confidence interval to evaluate the strength of 
the association and the precision of the effect.
Results
Mycobacterium tuberculosis strains isolated from 122 
patients (85.9 %) were found to be susceptible to all four 
first-line drugs tested, the remaining 20 strains (14.1 %) 
were resistant to at least one anti-TB drug. The highest 
resistance rate was seen for INH with 17 strains (12 %), 
followed by SM (4.9 %, n = 7), EMB (4.2 %, n = 6), and 
RIF (3.5  %, n  =  5). Monoresistance rate was also the 
highest for INH with nine strains (6.3  %), being 1.4  % 
(n = 2) and 0.7 % (n = 1) for SM and EMB, respectively. 
In the absence of monoresistance to RIF, all RIF-resistant 
cases were found to have MDR-TBM (Table  1). In this 
study, five of nine cases with INH-monoresistance were 
reported from Turkey, two from France, one from Den-
mark, and one from Romania.
Characteristic features and comorbid conditions of 
tuberculous meningitis patients and the distribution of 
drug susceptibility according to the countries participat-
ing in the study are shown in Tables 2, 3 respectively.
Overall, MDR-TBM was identified in five patients 
(3.5 %), all of which were new cases (three from Turkey, 
two from Serbia). Among MDR-TBM cases, two patients 
were also resistant to EMB and two patients were also 
resistant to EMB and SM, while one patient was not 
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resistant to any drugs tested other than RIF and INH. 
HIV status was available for only 128 cases. Of these, only 
three patients (2.3 %) were positive for HIV. On the other 
hand, all of the MDR-TBM cases were HIV-negative.
The overall mortality rate was 24.6 % with 35 cases. All 
patients, but one have died during treatment. The median 
time of death was 37 days (min: 1, max: 692). The average 
treatment duration in patients died were 4.4 months, and 
it was 12.7 months in the survivors.
Mortality was seen in 23.8 % (n = 29) of fully suscepti-
ble cases, in 30 % (n = 6) of those who were resistant to 
at least one anti-TB drug, in 33.3 % (n = 3) of cases who 
exhibited monoresistance to INH, and in 40  % (n  =  2) 
of cases with MDR-TBM. In comparison with patients 
without resistance to any all first-line drugs, the relative 
risk of death for INH-monoresistance and MDR-TBM 
was 1.60 (95  % CI, 0.38–6.82) and 2.14 (95  % CI, 0:34–
13:42), respectively. However, these differences were not 
statistically significant.
Discussion
Tuberculous meningitis is the most severe clinical form 
of disease caused by M. tuberculosis [4, 8]. It represents 
approximately 1 % of all TB cases, but is disproportion-
ately important because it results in unfavorable out-
comes including death and sequelae in one-third of the 
patients treated with antituberculous medications [9–11]. 
Therefore, early initiation of effective anti-TB therapy is 
essential for the success of TBM treatment [5]. However, 
in accordance with increasing drug resistance seen in 
TB cases worldwide, the number of drug-resistant TBM 
cases has been on the incline, making drug-resistant 
TBM a more challenging clinical problem [2, 8, 11].
Our results showed that, although 85.9 % of TBM cases 
were susceptible to four first-line drugs tested, 14.1  % 
were resistant to at least one anti-TB drug. According to 
the joint annual report by ECDC (European Centre for 
Disease Prevention and Control) and the WHO regional 
office for Europe, tuberculosis surveillance and moni-
toring in Europe 2014, the prevalence of resistance to at 
least one anti-TB drug in all TB cases is 12.7  % across 
European Union (EU) countries [12]. Given that the iso-
lates tested in our study were obtained basically from 
European countries, it can be expected that the rate of 
susceptibility to all the four first-line drugs in our TBM 
cases would likely to be similar to that reported for all 
TB cases. This finding suggests that, in cases diagnosed 
with TBM, prompt initiation of standard empiric anti-
TB treatment without awaiting the results of DST would 
not cause any problems in terms of drug resistance in 
about 85 % of cases. The rate of resistance to at least one 
drug in TBM cases was reported as 17.8  % from India, 
similar to that of our finding [7]. Another study con-
ducted in Vietnam reported this rate as high as 40 % and 
Table 1 First-line drug resistance rates of  M. tuberculosis 
strains isolated from cerebrospinal fluids
SM streptomycin, INH isoniazid, RIF rifampicin, EMB ethambutol
n %
Total number of strains tested 142 100.0
Susceptible to all four drugs 122 85.9
Any resistance 20 14.1
INH 17 12.0
RIF 5 3.5
EMB 6 4.2
SM 7 4.9
Monoresistance 12 8.5
INH 9 6.3
RIF 0 0.0
EMB 1 0.7
SM 2 1.4
Multidrug Resistance (MDR) 5 3.5
INH + RIF 1 0.7
INH + RIF + EMB 2 1.4
INH + RIF + EMB + SM 2 1.4
Other patterns 3 2.1
INH + SM 2 1.4
INH + EMB + SM 1 0.7
Table 2 Characteristics and drug susceptibility patterns of tuberculous meningitis patients
MDR multidrug resistance, INH isoniazid, DM diabetes mellitus, CKD chronic kidney disease, IS immunosupression
Drug resistance Age (median, range) Gender (male) 
 n (%)
Malignity  
n (%)
DM  
n (%)
CKD  
n (%)
IS  
n (%)
HIV  
n (%)
Dead  
n (%)
Fully sensitive (n: 122) 45.9 (17–87) 60 (49.2) 6 (4.9) 22 (18.0) 5 (4.1) 16 (13.1) 2 (1.6) 29 (23.8)
Monoresistance to INH 
(n: 9)
35.4 (19–89) 1 (11.1) – 1 (11.1) 1 (11.1) 1 (11.1) 1 (11.1) 3 (33.3)
MDR (n: 5) 37.6 (19–70) 1 (20.0) – 1 (20.0) – 1 (20.0) – 2 (40.0)
Other patterns (n: 6) 43.3 (28–81) 4 (16.7) – – 1 (16.7) – – 1 (16.7)
Total (n: 142) 44.9 (17–89) 66 (46.5) 6 (4.2) 24 (12.7) 7 (4.9) 18 (16.9) 3 (2.1) 35 (24.6)
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drew attention to the problem of drug-resistant TBM 
[13].
Among the first-line anti-TB agents, INH represents 
one of the most valuable drugs in the treatment of TBM, 
in that it has good CSF penetration and has early bacte-
ricidal activity. Therefore, INH resistance can be consid-
ered to affect the success of TBM treatment more than 
that of pulmonary TB [2, 5, 7]. Continuation phase of 
treatment containing three drugs as a daily regimen 
should be given in countries with high levels of INH 
resistance in new TB patients, and where INH drug sus-
ceptibility testing in new patients is not done [7]. In our 
study, overall and monoresistance rates for INH were 
12 and 6.3 %, respectively. These rates were higher than 
those found for other first-line drugs tested. Monoresist-
ance to INH has been reported to have the highest rate in 
TBM cases in other studies [7, 14]. INH resistance in pul-
monary TB cases was found to be 10 % in the European 
Union countries, with a higher rate of 15  % in Turkey 
[12]. These data suggest that INH resistance rates across 
this region are similar for pulmonary and central nervous 
system TB.
Reported rates of INH-monoresistance range from 6 
to 6.5 % in TBM cases in accordance with our findings. 
These cases have significantly higher mortality rates com-
pared to those with susceptibility to all first-line drugs 
[5, 15]. A study reported that 35 % of patients with INH-
monoresistance and 28  % of patients with susceptibil-
ity to all first-line drugs died during treatment [5]. The 
mortality rates in our cohort are 33.3 % in patients with 
INH-monoresistance, compared with 23.8  % in patients 
without resistance to any first-line drugs. However, this 
difference was not statistically significant probably due to 
the low number of cases with resistance in our cohort.
In some regions in the world, nearly one-third of all 
TB cases is MDR [2]. The rate of MDR-TB among all TB 
cases has been reported to be about 5 % in the European 
Union countries and in Turkey [12]. Studies that report 
MDR-TBM rates among TBM patients are limited in 
number, most of which come from areas with high TB 
prevalence [7, 16]. These rates range from 4.3 to 8.6  % 
for Vietnam and South Africa [13, 15, 16] and from 1.5 to 
2.4 % for the United States and India [7, 17]. There were 
only five (3.5 %) cases of MDR-TBM in our study, three 
from Turkey and two from Serbia.
According to the 2014 ECDC report, mortality occurred 
in 7.4 % of all TB cases across the European Union, with 
a striking rise to 17.8 % in MDR-TB patients; these rates 
were reported as 3.3 and 8.0  % for Turkey, respectively 
[12]. Although mortality rates for TBM and MDR-TBM 
were not specified in this report, these two conditions 
would apparently present with higher rates due to more 
severe disease characteristics [11, 16]. In preantibiotic era, 
the mortality rate in TB was 58 % [18]. In a recent meta-
analysis, the average mortality rate in adult TBM cases in 
Africa was calculated as 60  % [19]. Several studies exist 
reporting that MDR is one of the most important prog-
nostic factors for TBM, leading to significantly shorter sur-
vival [2, 8, 15]. In a study involving 180 adults with TBM, 
overall mortality rate was reported as 33.3 %, where all the 
patients with MDR-TBM (n = 10) died before completing 
the treatment (relative risk of death, 11.63; 95 % CI, 5.21–
26.32) [13]. Another study reported mortality rates as 73 
and 29  % among TBM patients with and without MDR, 
respectively, where MDR existence presented a relative 
risk of death of 2.49 (95 % CI, 1.95–3.18) [17]. In our study, 
the mortality rate of patients with MDR-TBM was higher 
(40.0 %) than that of cases with susceptibility to all drugs 
(23.8 %), and the relative risk of death for MDR-TBM was 
2.14 (95 % CI, 0:34–13:42). As in monoresistance issue we 
could not display a statistically significant association for 
MDR isolates and mortality probably due to low numbers.
Table 3 The distribution of drug susceptibility according to the countries participating in the study
R any resistance, TBM tuberculous meningitis, MDR multidrug resistance, INH isoniazid
Country Number of strains 
tested
R  
n (%)
INH-monoresistance 
n (%)
MDR-TBM  
n (%)
Other patterns 
n (%)
Dead  
n (%)
Resistance of strains 
from patiens dead 
n (%)
Turkey 69 12 (17.4) 5 (7.2) 3 (4.3) 4 (5.8) 9 (13.3) 2 (22.2)
Denmark 25 1 (4.0) 1 (4.0) – – 8 (32.0) 1 (12.5)
Croatia 19 – – – – 9 (47.4) –
Serbia 11 2 (18.2) – 2 (18.2) – 5 (45.5) 1 (20.0)
France 9 4 (44.4) 2 (22.2) – 2 (22.2) 3 (33.3) 2 (66.7)
Hungary 4 – – – – – –
Slovenia 3 – – – – 1 (33.3) –
Albania 1 – – – – – –
Romania 1 1 (100.0) 1 (100.0) – – – –
Total 142 20 (14.1) 9 (6.3) 5 (3.5) 6 (4.2) 35 (24.6) 6 (17.1)
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A meta-analysis of studies conducted in Africa reported 
the prevalence of HIV positivity in a range of 55 to 88 % 
among TBM patients [19]. HIV epidemics complicated by 
poor TB control programs resulted in increased number 
of MDR-TB cases, thus causing more and more patients 
to develop MDR-TBM in the past. The treatment of 
MDR-TBM is more challenging in HIV-positive patients, 
with a fatal course in more than 60 % of the cases [7, 11, 
15, 20]. A striking difference was reported between the 
mortality rates of HIV-infected patients with and without 
MDR-TBM (88  % vs. 49  %). In addition, HIV infection 
can be considered a risk factor for MDR-TBM [17, 21]. 
The majority of studies on patients with coexistent HIV 
and MDR-TBM come from areas where both conditions 
manifest high prevalences. A study from Vietnam found 
HIV-positivity rates as 22.2 and 45.5  % in patients with 
TBM in absence of MDR and MDR-TBM, respectively, 
with insignificant associations between the patients with 
HIV infection and MDR-TBM [13]. In contrast, another 
study from the United States reported the coexistence of 
HIV infection in 89 % of MDR-TBM patients and found a 
strong correlation between HIV infection and MDR [17]. 
According to the 2014 ECDC report, although 5.5  % of 
all TB cases in the European Union countries had HIV 
infection, this rate was 0.5 % in Turkey [12]. There were 
only three HIV-positive patients (2.3 %) and all of MDR-
TBM cases are HIV-negative in our study, because of the 
imbalanced recruitment of patients mainly from Turkey. 
It was not possible to assess the effect of HIV infection 
on the development of MDR-TBM and on mortality due 
to the small number of patients with positive HIV status. 
Consequently, comorbid conditions were not shown to 
affect TBM deaths in this study.
In MDR-TB cases, resistance to other anti-TB drugs 
other than INH and RIF has also been frequently 
reported [17]. In our study, two out of five MDR-TBM 
cases exhibited resistance to EMB, and the other two 
to both EMB and SM. In general, rifampicin resistance 
is considered to be a good marker to detect MDR-TB 
[22, 23]. This was consistent with our finding, in that all 
patients with resistance to RIF are MDR-TBM cases. Lit-
erature data supported by our finding suggest that utiliza-
tion of molecular tests for the detection of RIF resistance 
alone may prove to be helpful in the rapid diagnosis of 
MDR-TBM [22]. However, it should be kept in mind that 
this can’t detect INH-monoresistance in which the treat-
ment will be adversely affected.
Monoresistance to EMB is rare and there was no evi-
dence of the negative effect of monoresistance to SM 
on TBM treatment [15]. Among our cases, only three 
patients exhibited monoresistance to EMB (n = 1) or SM 
(n = 2), and one of this patients with SM-monoresistance 
dead during treatment.
One limitation to the study is that participating cent-
ers used different DST methods owing to the retrospec-
tive nature of the study. However, it would very difficult 
to provide such a large TBM cohort prospectively. The 
numbers of INH monoresistant and MDR-TBM cases 
were low in our study and because of this, it lacked statis-
tical power at this point.
Conclusion
In conclusion, based on our findings, it can be inferred 
that INH-resistance and MDR seem not to be worrisome 
in TBM cases in our study. However, considering their 
adverse effects on treatment, early and prompt detection 
of at least INH- and RIF-resistance would be most ben-
eficial for designing anti-TB therapy. Still, empiric TBM 
treatment should be started immediately while DST 
results are pending.
Authors’ contributions
SS, NO and HE designed and conducted the study. The other authors contrib‑
uted equally to this study. All authors read and approved the final manuscript.
Author details
1 Department of Infectious Diseases and Clinical Microbiology, Haydarpasa 
Numune Training and Research Hospital, Istanbul, Turkey. 2 Department 
of Medical Microbiology, Celal Bayar University School of Medicine, Manisa, 
Turkey. 3 Department of Infectious Diseases and Clinical Microbiology, 
Gulhane Medical Academy, Etlik, Ankara, Turkey. 4 Department of Infectious 
Diseases Q, Odense University Hospital, Odense, Denmark. 5 Department 
of Infectious Diseases, Dr. Fran Mihaljevic University Hospital for Infectious Dis‑
eases, University of Zagreb School of Medicine, Zagreb, Croatia. 6 Department 
of Infectious Diseases and Clinical Microbiology, Cukurova University School 
of Medicine, Adana, Turkey. 7 Department of Infectious Diseases and Clinical 
Microbiology, Inonu University School of Medicine, Malatya, Turkey. 8 Depart‑
ment of Infectious Diseases and Clinical Microbiology, Baskent University 
School of Medicine, Adana, Turkey. 9 Department of Infectious Diseases 
and Clinical Microbiology, Cumhuriyet University School of Medicine, Sivas, 
Turkey. 10 National Reference Laboratory for Tuberculosis, Institute of Microbi‑
ology and Immunology, Faculty of Medicine, University of Belgrade, Belgrade, 
Serbia. 11 Department of Infectious and Tropical Diseases, University Hospital 
of Pontchaillou, Rennes, France. 12 Department of Infectious Diseases and Clin‑
ical Microbiology, Uludag University School of Medicine, Bursa, Turkey. 13 Clinic 
for Infectious and Tropical Diseases, Clinical Centre of Serbia, Faculty of Medi‑
cine, University of Belgrade, Belgrade, Serbia. 14 Department of Infectious 
Diseases, Saint Laszlo Hospital, Budapest, Hungary. 15 Department of Infec‑
tious Diseases and Clinical Microbiology, Ege University School of Medicine, 
Izmir, Turkey. 16 Department of Infectious Diseases and Clinical Microbiology, 
Ondokuz Mayis University School of Medicine, Samsun, Turkey. 17 Department 
of Infectious Diseases and Clinical Microbiology, Istanbul University Cerrah‑
pasa School of Medicine, Istanbul, Turkey. 18 Department of Infectious Diseases 
and Clinical Microbiology, Erciyes University School of Medicine, Kayseri, Tur‑
key. 19 Department of Infectious Diseases, University Medical Centre, Ljubljana, 
Slovenia. 20 Department of Infectious Diseases and Clinical Microbiology, Lutfi 
Kirdar Training and Research Hospital, Istanbul, Turkey. 21 Department of Infec‑
tious Diseases, Poitiers University Hospital, Poitiers, France. 22 IPH of Vojvo‑
dina, Department of Prevention and Control of Diseases, Medical Faculty, 
University of Novi Sad, Novi Sad, Serbia. 23 Department of Infectious Diseases 
and Clinical Microbiology, Dicle University School of Medicine, Diyarbakir, 
Turkey. 24 Department of Infectious Diseases and Clinical Microbiology, Haseki 
Training and Research Hospital, Istanbul, Turkey. 25 Department of Infectious 
Diseases, Dax Hospital, Dax, France. 26 Service of Infectious Disease, University 
Hospital Center of Tirana, Tirana, Albania. 27 Department of Infectious Diseases, 
University Hospital, Strasbourg, France. 28 Department of Infectious Diseases 
and Clinical Microbiology, Adnan Menderes University School of Medicine, 
Aydin, Turkey. 29 Department of Infectious Diseases and Clinical Microbiology, 
Page 6 of 6Senbayrak et al. Ann Clin Microbiol Antimicrob  (2015) 14:47 
Tepecik Training and Research Hospital, Izmir, Turkey. 30 Department of Infec‑
tious Diseases and Clinical Microbiology, GATA Haydarpasa Training Hospital, 
Istanbul, Turkey. 31 Department of Infectious Diseases and Clinical Microbiol‑
ogy, Ataturk University School of Medicine, Erzurum, Turkey. 32 Department 
of Infectious Diseases and Clinical Microbiology, Onsekiz Mart University 
School of Medicine, Canakkale, Turkey. 33 Department of Infectious Diseases 
and Clinical Microbiology, Ankara University School of Medicine, Ankara, Tur‑
key. 34 Department of Infectious Diseases and Clinical Microbiology, Goztepe 
Training and Research Hospital, Medeniyet University, Istanbul, Turkey. 
Competing interests
The authors declare that they have no competing interests.
Received: 4 August 2015   Accepted: 12 October 2015
References
 1. WHO. Global tuberculosis report 2014. World Health Organization, 2014, 
Geneva, Switzerland. [WHO/HTM/TB/2014.08].
 2. Starke JR. Mycobacterial infections. Handb Clin Neurol. 2010;96:159–77.
 3. Erdem H, Ozturk‑Engin D, Elaldi N, Gulsun S, Sengoz G, Crisan A, et al. The 
microbiological diagnosis of tuberculous meningitis: results of Haydar‑
pasa‑1 study. Clin Microbiol Infect. 2014;20:O600–8.
 4. Bennett JE. Chronic meningitis. In: Bennett JE, Dolin R, Blaser MJ, editors. 
Mandell, Douglass, and Bennett’s principles and practice of infectious 
diseases. Philadelphia: Elsevier Co; 2015. p. 1138–43.
 5. Vinnard C, Winston CA, Wileyto EP, Macgregor RR, Bisson GP. Isoniazid 
resistance and death in patients with tuberculous meningitis: retrospec‑
tive cohort study. BMJ. 2010;341:c4451.
 6. Byrd TF, Davis LE. Multidrug‑resistant tuberculous meningitis. Curr Neurol 
Neurosci Rep. 2007;7(6):470–5.
 7. Nagarathna S, Rafi W, Veenakumari HB, Mani R, Satishchandra P, Chan‑
dramuki A. Drug susceptibility profiling of tuberculous meningitis. Int J 
Tuberc Lung Dis. 2008;12(1):105–7.
 8. Duo L, Ying B, Song X, Lu X, Ye Y, Fan H, Xin J, Wang L. Molecular profile 
of drug resistance in tuberculous meningitis from southwest china. Clin 
Infect Dis. 2011;53(11):1067–73.
 9. Erdem H, Ozturk‑Engin D, Tireli H, Kilicoglu G, Defres S, Gulsun S, 
et al. Hamsi scoring in the prediction of unfavorable outcomes from 
tuberculous meningitis: results of Haydarpasa‑II study. J Neurol. 2015;. 
doi:10.1007/s00415‑014‑7651‑5.
 10. Ducomble T, Tolksdorf K, Karagiannis I, Hauer B, Brodhun B, Haas W, Fiebig 
L. The burden of extrapulmonary and meningitis tuberculosis: an investi‑
gation of national surveillance data, Germany, 2002 to 2009. Euro Surveill 
2013;8(12). (pii:20436).
 11. Thwaites GE, van Toorn R, Schoeman J. Tuberculous meningitis: more 
questions, still too few answers. Lancet Neurol. 2013;12(10):999–1010.
 12. ECDC. Tuberculosis surveillance and monitoring in Europe 2014 Surveil‑
lance Report.
 13. Thwaites GE, Lan NT, Dung NH, Quy HT, Oanh DT, Thoa NT, et al. Effect of 
antituberculosis drug resistance on response to treatment and outcome 
in adults with tuberculous meningitis. J Infect Dis. 2005;192(1):79–88.
 14. Gautam VKS, Khurana S, Singh R. Multi drug resistant (MDR) tuberculous 
meningitis with hydrocephalus treated with ventriculo‑peritoneal shunt‑
ing: a review. Int J Med. 2015;3(1):22–5.
 15. Tho DQ, Torok ME, Yen NT, Bang ND, Lan NT, Kiet VS, et al. Influence of 
antituberculosis drug resistance and Mycobacterium tuberculosis line‑
age on outcome in HIV‑associated tuberculous meningitis. Antimicrob 
Agents Chemother. 2012;56(6):3074–9.
 16. Patel VB, Padayatchi N, Bhigjee AI, Allen J, Bhagwan B, Moodley AA, 
Mthiyane T. Multidrug‑resistant tuberculous meningitis in KwaZulu‑Natal. 
South Africa. Clin Infect Dis. 2004;38(6):851–6.
 17. Vinnard C, Winston CA, Wileyto EP, MacGregor RR, Bisson GP. Multidrug 
resistant tuberculous meningitis in the United States, 1993–2005. J Infect. 
2011;63(3):240–2.
 18. Erdem H, Tetik A, Arun O, Besirbellioglu BA, Coskun O, Eyigun CP. War and 
infection in the pre‑antibiotic era: the third ottoman army in 1915. Scand 
J Infect Dis. 2011;43(9):690–5.
 19. Woldeamanuel YW, Girma B. A 43‑year systematic review and meta‑
analysis: case‑fatality and risk of death among adults with tuberculous 
meningitis in Africa. J Neurol. 2014;261(5):851–65.
 20. Daikos GL, Cleary T, Rodriguez A, Fischl MA. Multidrug‑resistant 
tuberculous meningitis in patients with AIDS. Int J Tuberc Lung Dis. 
2003;7(4):394–8.
 21. Suchindran S, Brouwer ES, Van Rie A. Is HIV infection a risk factor for 
multi‑drug resistant tuberculosis? A systematic review. PLoS ONE. 
2009;4(5):e5561.
 22. Drobniewski F, Nikolayevskyy V, Balabanova Y, Bang D, Papaventsis D. 
Diagnosis of tuberculosis and drug resistance: what can new tools bring 
us? Int J Tuberc Lung Dis. 2012;16(7):860–70.
 23. Sharma K, Modi M, Kaur H, Sharma A, Ray P, Varma S. rpoB gene high‑
resolution melt curve analysis: a rapid approach for diagnosis and screen‑
ing of drug resistance in tuberculous meningitis. Diagn Microbiol Infect 
Dis. 2015;83(2):144–9.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
